ArticleReviews in cardiovascular medicine2026
Exploration of the Clinical Assessment and Prognostic Value of Society for Cardiovascular Angiography and Intervention Shock Staging in Patients With Acute Myocardial Infarction and Cardiogenic Shock on Veno-arterial Extracorporeal Membrane Oxygenation Support.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although the Society for Cardiovascular Angiography and Intervention (SCAI) five-stage system provides a structured approach to shock assessment, the prognostic utility of this system in patients with acute myocardial infarction and cardiogenic shock (AMICS) supported by venoarterial extracorporeal membrane oxygenation (VA-ECMO), particularly when combined with dynamic cardiac biomarkers, has not been fully validated. Methods: This single-center, hospital-based, prospective registry study, we continuously enrolled patients with AMICS who received VA-ECMO support at the Cardiac Centre of the First Hospital of Lanzhou University between January 2020 and October 2023, using data from the Chinese Society of Extracorporeal Life Support (CSECLS) registry. Patients were assigned to Stage D or E groups according to the SCAI shock staging system. Clinical characteristics and biomarkers were compared between the two groups, and a multivariate logistic regression model was used to examine the associations among shock stage, cardiac biomarkers, and in-hospital mortality. Results: This study included 119 patients with AMICS receiving VA-ECMO support, of whom 78 were classified as Stage D and 41 as Stage E. Compared with Stage D patients, Stage E patients had lower VA-ECMO survival scores (-10 vs -2; Conclusion: Combining SCAI shock staging with the dynamic monitoring of cardiac biomarkers facilitates the early risk stratification in patients with AMICS receiving VA-ECMO support, and demonstrates good predictive value for in-hospital mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.